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terms in the treatment selection equation and the TED equation
proved to be independent we re-estimated by univariate probit.
Sensitivity analyses estimating the effect of olanzapine, risperi-
done and quetiapine independently versus TAP were also con-
ducted. RESULTS: A Wald test of the correlation coefﬁcient of
the disturbances suggests that treatment selection is exogenous
in our model (rho = −0.049 (p = 0.57)) using a Huber-White
sandwich estimator of the variance. The univariate probit para-
meter estimates of AAP is statistically signiﬁcantly positive (p =
0.044) suggesting that AAP are associated with an increased risk
of TED relative to TAP. The marginal effect of AAP is 0.0827;
that is the TED propensity of AAP is 8.27% higher than that of
TAP. A univariate probit model demonstrated that olanzapine (p
= 0.10), quetiapine (p = 0.10) and risperidone (p = 0.31) were
independently associated with an increased risk of TED, though
not signiﬁcantly. A bivariate probit model omitting prior comor-
bidity, drug use and quarterly dummy variables demonstrates
selection bias (rho = −0.650 (p = 0.0029)). CONCLUSION: The
results of this study show that AAP are associated with an
increased risk of TED relative to TAP. Evidence of unobserved
selection bias was not present. Explanatory variables that may
explain treatment selection that were included in our model were
sufﬁcient to control for choice of therapy.
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OBJECTIVES: The association between suicidality and antide-
pressant use has been reported in literature using clinical trial
data. This study 1) investigates the relationship between suici-
dality and antidepressants use in children and adolescents using
managed care claims data; 2) examines the effect of an FDA
black box warning on antidepressant use in children and ado-
lescents. METHODS: Subjects 5–19 years old, continuously
enrolled in a large Midwestern IPA model health plan, diagnosed
with depression (using ICD-9-CM codes) or issued at least one
antidepressant prescription between January 1, 2004 and June
30, 2005 were included in the study. Descriptive statistics, paired
samples t-test, Chi-Square test, and stepwise logistic regression
were used to analyze the data. RESULTS: A total of 5104 sub-
jects (7.2% continuously enrolled in 5–19 year olds) met the
study criteria; 53% female; mean age was 15 years; 67% had
depression diagnosis. Antidepressant use was modestly associ-
ated with suicidality using Chi-square test (x2 = 3.03, p = 0.08;
contingency odds ratio = 1.67). Logistic regression showed that
antidepressant use is not a signiﬁcant predictor to suicidality,
while gender, depression diagnosis, other comorbid mental
health, drug and alcohol abuse, and specialty provider were sig-
niﬁcant predictors to suicidality. While average days on antide-
pressant drug therapy decreased signiﬁcantly (p = 0.009) after
the black box warning, the number of inpatient stays for depres-
sion after the black box warning increased signiﬁcantly (p =
0.007). CONCLUSION: From this claims database, the associ-
ation between suicidality and antidepressant use in children and
adolescents is not clear. Caution is needed in the use of antide-
pressants in this population. Increased inpatient stays following
the black box warning may be an indication that providers are
more aware of the suicidality risk or due to decreased use of anti-
depressants. It is important to balance appropriate usage and
concerns for the safety of medications with the risk of adverse
events and subsequent health service use.
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OBJECTIVES: Depression is the most prevalent major mental
health disorder, affecting between eight and ten percent of the
U.S. population. The U.S. Medicaid programs spent approxi-
mately $2 billion on antidepressant drugs in 2005, across three
categories of antidepressants including selective serotonin reup-
take inhibitors, tricyclic antidepressants, and other antidepres-
sants. Predicting future prices and utilization of antidepressants
would facilitate Medicaid’s planning process. Our objective is to
build forecasting models that can be used to improve Medicaid’s
budgeting efforts. METHODS: We gather quarterly data
(1991–2004, Centers for Medicare & Medicaid Services) on
Medicaid national antidepressant expenditure. We use Box-
Jenkins forecasting techniques on expenditure and utilization
time series for speciﬁc antidepressants including Paxil, Prozac,
Wellbutrin and Zoloft. Intervention analysis is used to determine
the effects of patent expiration, new branded-drug entry, and
new indication approval. Forecasts are computed and compared
to a holdout sample, comprised of the 2005 data, to assess the
performance of the models. RESULTS: The Box-Jenkins ARIMA
algorithms for ﬁtting and diagnosing the expenditure and uti-
lization data resulted in four distinct non-stationary forecasting
models. Final models were selected using standard information-
based criteria. The Paxil and Prozac models incorporated an
intervention term corresponding to patent expiration: a step
function for Paxil and an exponential decay for Prozac. The best
ﬁtting model for Wellbutrin is a third order moving average in
the ﬁrst differences; the Zoloft model is a Random Walk.
Maximum likelihood was used for estimations. Usual checks on
the residuals proved to be satisfactory. CONCLUSION: ARIMA
modeling can be used to capture the time series of individual
antidepressant drugs purchased by Medicaid. Moreover, inter-
vention analysis can be used to demonstrate the effect that
generic entry has on the utilization of or expenditure on a
branded medication. We ﬁnd that the drugs studied are affected
differently by this type of event.
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OBJECTIVES: To analyze, from a payer perspective, the net
beneﬁt of prescribing divalproex sodium extended-release
(DVPX-ER) versus valproic acid (VPA) in patients who suffer
from bipolar disorder. METHODS: The study used a decision
analytic framework to compare the net beneﬁt of DVPX-ER rel-
ative to VPA in the treatment of bipolar disease. The decision
model incorporated on two primary outcomes: GI side effects,
and treatment success. Levels of health service utilization and
probability values were obtained from an expert panel comprised
of 15 psychiatrists. Costs were obtained from an academic
medical center. Two-way sensitivity analysis on the probability
of GI events and the probability of disease control for VPA was
used to provide further insight regarding the set of combinations
of values in the model consistent with the decision to use VPA
and DVPX-ER. RESULTS: The average probability of GI side
